BioSpace News Archive

Innate Pharma SA announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below.

Orexo AB, announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Medicenna Therapeutics Corp. announced that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC, which notified the Company of the delisting of its securities from the Nasdaq Capital Market as a result of the Company’s failure to comply with the US$1.00 per share minimum bid price requirement.

Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited (“Intas”) for the development and commercialisation in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG (serplulimab injection), Henlius’ novel anti-PD-1 mAb.

BiomX Inc. announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in people with cystic fibrosis at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona.

Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the device at the 35th Transcatheter Cardiovascular Therapeutics (TCT) conference.

L2P Research, LLC, a leading preclinical CRO, today announced the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the third quarter 2023 and corporate updates, before market open on Thursday, November 9, 2023.

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.

TransCode Therapeutics, Inc. announced The Nasdaq Hearings Panel granted the Company’s request to continue its listing on The Nasdaq Stock Market Based on information the Company presented to the Panel, the Panel granted the Company’s request for an exception until January 22, 2024, subject to the conditions outlined below.